行情

TPTX

TPTX

Turning Point Therapeutics Inc
NASDAQ

实时行情|Nasdaq Last Sale

36.90
+0.35
+0.96%
盘后: 36.90 0 0.00% 16:00 10/18 EDT
开盘
35.85
昨收
36.55
最高
37.09
最低
35.80
成交量
36.00万
成交额
--
52周最高
58.56
52周最低
24.21
市值
7.53亿
市盈率(TTM)
-80.7793
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

TPTX 新闻

  • 通用汽车罢工刚结束 沃尔沃麦克卡车工厂也开始罢工
  • 新浪美股.1小时前
  • "既当球员又当裁判"?波音工程师的"双重身份"引担忧
  • 新浪美股.1小时前
  • 自2016年以来 企业利润从未面临如此大的压力
  • 新浪美股.3小时前
  • 瑞银董事长警告:英国脱欧或引发广泛的"投资者罢工"
  • 新浪美股.4小时前

更多

所属板块

生物技术和医学研究
-1.17%
制药与医学研究
-0.94%

热门股票

名称
价格
涨跌幅

TPTX 简况

Turning Point Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies. Its tyrosine kinase inhibitors (TKIs) pipeline targets numerous genetic drivers of cancer in both TKI-naive and TKI-pretreated patients. The Company has developed a macrocycle platform enabling to design proprietary small, compact TKIs with rigid three-dimensional structures that potentially bind to their targets with greater precision and affinity than other kinase inhibitors. The Company’s lead drug candidate, repotrectinib (TPX-0005), is being evaluated in an ongoing Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors.
展开

Webull提供Turning Point Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。